SCHEMBL5507692

SCHEMBL5507692

O=C(O)N1CCc2c(oc3ccccc23)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTHFD2 P13995 1/20 0.52
▸ HDAC1 Q13547 4/20 0.47
▸ NPC1 O15118 1/20 0.46
▸ SIGMAR1 Q99720 3/20 0.46
▸ HPGD P15428 5/20 0.43
▸ TSHR P16473 3/20 0.43
▸ HTT P42858 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ CTSK P43235 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ LMNA P02545 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ DRD4 P21917 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2978467 0.83 HDAC1 (0.47) MTHFD2HDAC1NPC1SIGMAR1HPGD
SCHEMBL5370174 0.83 MTHFD2 (0.73) MTHFD2NPC1HPGDSMN1; SMN2KDM4E
SCHEMBL15769678 0.81 HDAC1 (0.45) MTHFD2HDAC1RAB9ADRD4
SCHEMBL26675952 0.77 MTHFD2 (0.44) MTHFD2HDAC1NPC1SIGMAR1HPGD
SCHEMBL29736024 0.77 MTHFD2 (0.44) MTHFD2HDAC1NPC1SIGMAR1HPGD
SCHEMBL10385974 0.77 MEN1 (0.56) TSHRHTTSMN1; SMN2KDM4ETP53
Hydrochloric Acid SCHEMBL10387278 0.76 MEN1 (0.55) TSHRHTTSMN1; SMN2KDM4ETP53
Hydrochloric Acid SCHEMBL5503498 0.75 MTHFD2 (0.48) MTHFD2HDAC1NPC1SIGMAR1HPGD
SCHEMBL8033070 0.75 SIGMAR1 (0.50) HDAC1NPC1SIGMAR1HPGDTSHR
SCHEMBL15016186 0.75 DRD2 (0.46) HDAC1NPC1HPGDKDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831227-A2 NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS Glenmark Pharmaceuticals S.A. (CH) 2007-09-12 — — EP disclosed
WO-2006064355-A2 NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS GLENMARK PHARMACEUTICALS S.A. (US) 2006-06-22 — — WO disclosed
Send feedback